Lower respiratory tract infection

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

Retrieved on: 
Donnerstag, Mai 9, 2024
Brain, Coccidioides, Inflammation, Aspergillosis, Amphotericin B, Lecture, Lower respiratory tract infection, Safety, Skin, Antimicrobial, Conference call, Abstract, Fungal infection, Survival, Partnership, Cell, Research, Hepatocellular carcinoma, BioNTech, Patient, Gene, Society, Histoplasmosis, Lung, Malignancy, Toxicity, Manuscript, Standard of care, Infection, Annual general meeting, Platinum, LNC, Pharmaceutical industry

BEDMINSTER, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ending March 31, 2024 and provides a business update.

Key Points: 
  • Conference call begins at 4:30 p.m. Eastern time today
    BEDMINSTER, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ending March 31, 2024 and provides a business update.
  • “We are highly encouraged by results from in vivo studies demonstrating a substantial reduction in the well-recognized toxicity of IV-docetaxel.
  • Subsequent to the close of the quarter, in April the Company raised gross proceeds of $10.0 million through a registered direct offering.
  • The live webcast will be accessible on the Investors section of the company’s website and archived for 90 days.

ADLM releases guidance to help healthcare professionals navigate respiratory virus testing in a post-COVID world

Retrieved on: 
Donnerstag, Mai 2, 2024
Education, Laboratory, Virology, Medical laboratory, Research, AACC, DRS, Diagnosis, Patient, Pan American Society, Immunodeficiency, Respiratory tract infection, Infection, Lower respiratory tract infection, COVID-19, Vaccine

As respiratory virus testing continues to evolve rapidly in the wake of the COVID-19 pandemic, this guidance aims to ensure that patients benefit fully from emerging technologies in this field.

Key Points: 
  • As respiratory virus testing continues to evolve rapidly in the wake of the COVID-19 pandemic, this guidance aims to ensure that patients benefit fully from emerging technologies in this field.
  • Furthermore, the guidance document discusses the role of diagnostic stewardship in respiratory virus testing, which can help generate accurate and clinically relevant results while conserving laboratory resources.
  • Additionally, the authors of the guidance document propose an algorithm that can help laboratories efficiently decide on the most appropriate tests for a given case of respiratory virus infection.
  • "Laboratorians should remain alert and involved to provide guidance on managing testing and the information obtained from a wider range of testing settings."

The Lundquist Institute Receives $2.6 Million Grant from U.S. Army Medical Research Acquisition Activity to Develop Wearable Biosensors

Retrieved on: 
Donnerstag, April 25, 2024
UCLA, Mortality, Patient, Lower respiratory tract infection, Blood, Health, CRP, Death, Partnership, Doctor of Philosophy, Research, COPD, TLI, Electronics, Conditional sentence, AECOPD, Hospital, Perspiration, Infection, Disease, Chronic obstructive pulmonary disease, Pharmaceutical industry

Torrance, California, April 24, 2024 (GLOBE NEWSWIRE) -- The U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded The Lundquist Institute (TLI) a four-year grant totaling $2,623,234.

Key Points: 
  • Torrance, California, April 24, 2024 (GLOBE NEWSWIRE) -- The U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded The Lundquist Institute (TLI) a four-year grant totaling $2,623,234.
  • The research project is led by Dr. Harry Rossiter, an investigator at TLI and Professor at the David Geffen School of Medicine at UCLA.
  • The project aims to develop wearable multiplex biosensors to monitor exacerbation risk in chronic obstructive pulmonary disease (COPD).
  • COPD affects approximately 16 million Americans and is the third leading cause of death globally.

Migraine sufferers in England may soon be able to access preventative drug – here’s how atogepant works

Retrieved on: 
Dienstag, April 23, 2024
Migraine, Head, Sound, Headache, Dizziness, Aura, Liver disease, CGRP, Patient, Ageing, Light, Constipation, NHS, Fatigue, Food, Quality of life, Neuron, Woman, Nausea, Progress, DSM-IV codes, Lower respiratory tract infection, Anticonvulsant, Vomiting, Neck, Birth control

Atogepant (brand name: Aquipta) was recently recommended by the National Institute for Health and Care Excellence (Nice) to prevent episodic and chronic migraine attacks.

Key Points: 
  • Atogepant (brand name: Aquipta) was recently recommended by the National Institute for Health and Care Excellence (Nice) to prevent episodic and chronic migraine attacks.
  • The drug would be recommended to people who have at least four migraine days a month or where at least three previous preventative treatments have failed.
  • Migraine is a complex neurological condition that affects about 10 million people in the UK.
  • It’s characterised by recurrent, severe headaches that can be made worse by physical activity and are often debilitating.
  • However, it’s only suited to patients who suffer from episodic migraines – whereas atogepant can be used by people who have both chronic and episodic migraines.

Consistently effective


Three clinical trials have shown atogepant to be safe and effective for people with episodic or chronic migraines.

  • The Advance trial evaluated how safe and effective different doses of atogepant were compared with a placebo in preventing episodic migraine.
  • The 60mg once-daily tablet was found to be well tolerated and effective, leading to nearly seven fewer migraine days per month.
  • A third trial, the 302-LTS trial, followed participants who suffered from episodic migraine for over a year, finding that atogepant was consistently effective for reducing migraine attacks.
  • Atogenpant was consistently shown to be safe across all studies, including the one that lasted for a year.


Anna Andreou receives funding from the Medical Research Foundation and Brain Research UK. She also received research funding from eNeura, AbbVie and Pfizer. She is affiliated with the International Headache Society, being elected as a Trustee of the Board. She is Chair of the Headache special interest group of the British Pain Society.

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Withdrawn

Retrieved on: 
Donnerstag, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Absorption, Lower respiratory tract infection, Exercise, Cell, Infection, DSM-IV codes, Inflammation, Patient, Committee, Cystic fibrosis, Knowledge, Digestion, Regulation, Bacteria, Food, EMA, IRIS, Anti-inflammatory, Mucus, CB2, European, COMP, Pancreas, Sponsor, Ivacaftor, European Commission, Safety, CFTR, Marketing, Medicine, Pharmaceutical industry

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Withdrawn

Key Points: 


Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Withdrawn

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Positive

Retrieved on: 
Dienstag, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Absorption, Lower respiratory tract infection, Exercise, Cell, Infection, DSM-IV codes, Inflammation, Patient, Committee, Cystic fibrosis, Knowledge, Digestion, Regulation, Bacteria, Food, EMA, IRIS, Anti-inflammatory, Mucus, CB2, European, COMP, Pancreas, Sponsor, Ivacaftor, European Commission, Safety, CFTR, Marketing, Medicine, Pharmaceutical industry

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Positive

Key Points: 


Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Positive

ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Donnerstag, März 21, 2024
Research, Nitrosamine, Anaphylaxis, Symantec Endpoint Protection, Absorption, Human, ARS, MAA, Patent, Caregiver, PD, New Drug Application, SAN, Patient, Adrenaline, Journal, CRL, NDA, American Academy, EMA, Quality of life, Trial of the century, Flare, American College, Investment, Clinical trial, Erythema, Lower respiratory tract infection, Asthma, Body surface area, Itch, Allergy, FDA, AAAAI, Total, Food, Pharmaceutical industry

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the fourth quarter and full year 2023.

Key Points: 
  • In February 2024, ARS Pharma announced the successful completion of the repeat dosing study of neffy in seasonal allergic rhinitis under nasal allergen challenge conditions.
  • R&D Expenses: Research and development expenses were $3.4 million and $20.3 million for the quarter and year ended December 31, 2023, respectively.
  • G&A Expenses: General and administrative expenses were $6.8 million and $47.3 million for the quarter and year ended December 31, 2023, respectively.
  • Net Loss: Net loss was $7.2 million and $54.4 million for the quarter and year ended December 31, 2023, respectively.

Palestinian Journalist Samar Abu Elouf Wins IWMF 2024 Anja Niedringhaus Courage in Photojournalism Award

Retrieved on: 
Donnerstag, April 4, 2024
Hamas, The New York Times, Media Foundation, Black, Courage, Harvard University, Journalism, Zuma Press, TIME, Edge, Woman, Exhibition, Time (magazine), 2018–2019 Gaza border protests, NPR, Reuters, AP, Associated Press, IWMF, University, Niedringhaus, Great, ICRC, Professional, Indian Red Cross Society, Imperial, Lower respiratory tract infection, Associated, Environment, Trust, GOST, Empathy, COVID-19, Press, Pulitzer Prize, OPC, Overseas, Language, Collection, Nariman

WASHINGTON, April 4, 2024 /PRNewswire/ -- The International Women's Media Foundation (IWMF) today announced freelance photojournalist Samar Abu Elouf as the 10th annual recipient of its Anja Niedringhaus Courage in Photojournalism Award. The global recognition honors women photojournalists who document humanity amid conflict as well as the challenges facing marginalized populations worldwide. This year's award is being issued on April 4, 2024, the 10th anniversary of German photojournalist Anja Niedringhaus's passing; Niedringhaus was killed while on assignment in Afghanistan with the Associated Press.

Key Points: 
  • WASHINGTON, April 4, 2024 /PRNewswire/ -- The International Women's Media Foundation (IWMF) today announced freelance photojournalist Samar Abu Elouf as the 10th annual recipient of its Anja Niedringhaus Courage in Photojournalism Award .
  • This year's award is being issued on April 4, 2024, the 10th anniversary of German photojournalist Anja Niedringhaus 's passing; Niedringhaus was killed while on assignment in Afghanistan with the Associated Press.
  • "I am honored to receive this award, to be recognized for my work in Gaza, and to follow in the footsteps of Anja's courage," said Abu Elouf.
  • Anja Niedringhaus was a recipient of the IWMF Courage in Journalism Award in 2005.

Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

Retrieved on: 
Mittwoch, Februar 21, 2024
OTCQB, RSV, Virology, Nuclear magnetic resonance, Viral, Vaccine, Lower respiratory tract infection, University, COVID-19, Virus, Patient, Clinical trial, Molar, Carbohydrate, Mutation, Research

BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced that the first patients have been treated with ProLectin-M in its dose optimization trial. ProLectin-M is intended to become a first line treatment for standard risk COVID-19 patients, but based on the broad-spectrum in vitro discovery could easily expand to upper respiratory tract infections. Following this dose optimization trial, Bioxytran intends to use the trial data to inform the design of the Phase 3 registrational trial in India, while also adhering to the FDA’s request for additional data.

Key Points: 
  • Following this dose optimization trial, Bioxytran intends to use the trial data to inform the design of the Phase 3 registrational trial in India, while also adhering to the FDA’s request for additional data.
  • The multi-center clinical trial in India will be a randomized double-blind placebo-controlled trial and is set to enroll 40 patients.
  • “After we complete the dose optimization trial, the next regulatory milestone is a registrational trial,” said Dr. Leslie Ajayi, Bioxytran’s medical director.
  • “We are on the cusp of completing a clinical trial of standard risk patient that contracted COVID-19.

ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

Retrieved on: 
Dienstag, Februar 20, 2024
Allergy, Epinephrine autoinjector, SAN, EMA, PD, Caregiver, Committee, CRL, Doctor of Philosophy, RN, ARS, Absorption, FDA, Food, File, Anaphylaxis, Heart rate, NAC, PDUFA, Agency, Entrepreneurship, Complete Response Letter, FARE, Symantec Endpoint Protection, Safety, Health, Lower respiratory tract infection, University, Rhinitis, Nasal mucosa, CHMP, European Medicines Agency, Nitrosamine, Patient, Pediatrics, IM, Adrenaline, Translational research, Trial of the century, Pharmaceutical industry

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced topline results from its clinical study comparing repeat doses of neffy (epinephrine nasal spray) to repeat doses of epinephrine intramuscular (IM) injection, as requested by the FDA with and without nasal allergen challenge (NAC) conditions.

Key Points: 
  • “The study objective was to compare twice dosing with epinephrine injection and twice dosing with neffy under normal conditions and after nasal allergen challenge.
  • With these results, we are completing the necessary work to submit our response to FDA in the next couple of months.
  • The repeat dose study under NAC conditions was designed with the FDA to address the Agency’s outstanding questions regarding neffy as described in the Complete Response Letter (CRL) from September 2023.
  • In addition, multiple PADAC members highlighted the favorable profile of neffy in our single dose NAC study.